154 related articles for article (PubMed ID: 7893273)
1. Oral iron chelation therapy with deferiprone. Monitoring of biochemical, drug and iron excretion changes.
Kontoghiorghes GJ; Bartlett AN; Sheppard L; Barr J; Nortey P
Arzneimittelforschung; 1995 Jan; 45(1):65-9. PubMed ID: 7893273
[TBL] [Abstract][Full Text] [Related]
2. Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies.
Kontoghiorghes GJ; Bartlett AN; Hoffbrand AV; Goddard JG; Sheppard L; Barr J; Nortey P
Br J Haematol; 1990 Oct; 76(2):295-300. PubMed ID: 2094333
[TBL] [Abstract][Full Text] [Related]
3. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2- dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan.
Ayyub M; Ali W; Anwar M; Waqar A; Khan MN; Ijaz A; Hussain T; Hussain S
J Ayub Med Coll Abbottabad; 2005; 17(4):12-5. PubMed ID: 16599026
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome.
Cermak J; Jonasova A; Vondrakova J; Walterova L; Hochova I; Siskova M; Neuwirtova R
Hemoglobin; 2011; 35(3):217-27. PubMed ID: 21599434
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of 1-2, dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassaemia major with iron overload.
Agarwal MB; Gupte SS; Vasandani D; Viswanathan C; Puniyani RR; Ramanathan J; Massil DE; Shah S; Rajyadhyaksha GC; Bhave AA
J Assoc Physicians India; 1991 Sep; 39(9):669-72. PubMed ID: 1814897
[TBL] [Abstract][Full Text] [Related]
7. Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with homozygous beta-thalassemia.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Clin Pharmacol Ther; 1994 Jan; 55(1):70-5. PubMed ID: 8299320
[TBL] [Abstract][Full Text] [Related]
8. Erythropoietin administration may potentiate mobilization of storage iron in patients on oral iron chelation therapy.
Cermák J
Hemoglobin; 2006; 30(1):105-12. PubMed ID: 16540422
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major.
al-Refaie FN; Wonke B; Hoffbrand AV; Wickens DG; Nortey P; Kontoghiorghes GJ
Blood; 1992 Aug; 80(3):593-9. PubMed ID: 1638018
[TBL] [Abstract][Full Text] [Related]
10. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major.
Töndury P; Kontoghiorghes GJ; Ridolfi-Lüthy A; Hirt A; Hoffbrand AV; Lottenbach AM; Sonderegger T; Wagner HP
Br J Haematol; 1990 Dec; 76(4):550-3. PubMed ID: 2265118
[TBL] [Abstract][Full Text] [Related]
11. Combined oral and parenteral iron chelation in beta thalassaemia major.
Balveer K; Pyar K; Wonke B
Med J Malaysia; 2000 Dec; 55(4):493-7. PubMed ID: 11221163
[TBL] [Abstract][Full Text] [Related]
12. Iron chelation therapy.
Hoffbrand AV; Wonke B
J Intern Med Suppl; 1997; 740():37-41. PubMed ID: 9350180
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.
Kersten MJ; Lange R; Smeets ME; Vreugdenhil G; Roozendaal KJ; Lameijer W; Goudsmit R
Ann Hematol; 1996 Nov; 73(5):247-52. PubMed ID: 8959943
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
[TBL] [Abstract][Full Text] [Related]
15. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
[TBL] [Abstract][Full Text] [Related]
16. Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial.
Agarwal MB; Gupte SS; Viswanathan C; Vasandani D; Ramanathan J; Desai N; Puniyani RR; Chhablani AT
Br J Haematol; 1992 Oct; 82(2):460-6. PubMed ID: 1419829
[TBL] [Abstract][Full Text] [Related]
17. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
[TBL] [Abstract][Full Text] [Related]
18. Zinc concentration in patients with iron overload receiving oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one or desferrioxamine.
al-Refaie FN; Wonke B; Wickens DG; Aydinok Y; Fielding A; Hoffbrand AV
J Clin Pathol; 1994 Jul; 47(7):657-60. PubMed ID: 8089225
[TBL] [Abstract][Full Text] [Related]
19. Comparison of pharmacokinetics and urinary iron excretion of two single doses of deferiprone in β-thalassemia/hemoglobin E patients.
Rodrat S; Yamanont P; Tankanitlert J; Chantraraksri U; Fucharoen S; Morales NP
Pharmacology; 2012; 90(1-2):88-94. PubMed ID: 22759897
[TBL] [Abstract][Full Text] [Related]
20. Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia.
Olivieri NF; Koren G; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM
Blood; 1992 May; 79(10):2741-8. PubMed ID: 1586721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]